Global News

[ad_1] Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Friday's key moments. 1. Wall Street saw some volatility Friday around Federal Reserve Chairman Jerome Powell's morning speech from the central bank conference in Jackson Hole, Wyoming. Powell said inflation is still "too high" and the Fed is "prepared to raise rates further" if economic data dictates it. No interest rate hike is expected at next month's Fed meeting, according to the CME FedWatch tool . There's a split in the market on whether we'll see one more rate hike before year-end. Currently, no action is favored. 2. The overall market remains oversold, according to Jim Cramer's trusted S & P Oscillator , but not as oversold as it was earlier in the week. We've been making strategic buys all week long. One day after a blowout quarter, we boosted on Thursday our Nvidia (NVDA) pr

[ad_1] The launch of Eli Lilly 's weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said Friday. Weekly Zepbound prescriptions totaled 7,700 in the week ended Dec. 8, its fourth on the U.S. market, according to Jefferies, which cited data compiled by health-care analytics firm IQVIA. That is more than Novo Nordisk 's Wegovy — currently the most popular obesity drug in the country — had in its fourth week after being approved in 2021, Jefferies concluded. "Zepbound has shown strong launch momentum in the weeks following its first prescription recorded," the analysts wrote in a research note. That's an encouraging finding for investors, given it will be more than a month before Eli Lilly reports earnings with formal revenue contributions from its much-hyped obesity drug. The Club holding typically reports fourth-quarter results in late January or early February. To be sure

[ad_1] As Wall Street on Tuesday attempted to hold onto recent gains, we received positive updates on two Club holdings that are seeing outsized moves to the upside: Danaher (DHR) and Constellation Brands (STZ). DHR 1Y mountain Danaher's 1 year stock performance Danaher is set to present at the JPMorgan Healthcare Conference on Tuesday afternoon. However, ahead of the event, on Monday evening, the life sciences and medical diagnostics company released its slide deck. In addition to providing a high-level look at what the company will look like after the separation of its Environmental & Applied Solutions business, it included an upward revision to fourth-quarter guidance. Shares jumped 4% on the positive revision. Some investors were concerned that management would preannounce weak earnings. Now, management sees core sales growth up in the high single-digit range. The increase can be largely attributed to better-than-expected performance in Cepheid's molecular diagnost

[ad_1] Business at GE Healthcare Technologies capped off 2023 on a strong note despite ongoing concerns about China. That coupled with management's upbeat view of this year propelled shares up more than 13% to over $83 each at session highs. That was their highest level since July 2023. The Club stock closed just under $82. Total revenue increased more than 5% year over year to $5.21 billion, beating analysts' expectations of $5.1 billion, according to LSEG. Adjusted earnings-per-share (EPS) of $1.18 exceeded the LSEG estimate of $1.07. Bottom line We always say expectations matter when it comes to earnings season. Sometimes a company can do everything right and deliver a strong quarter but see its stock fall because expectations had gotten a little ahead of themselves. That was Eli Lilly , which also reported earnings Tuesday. In other examples, the stock is down so much that it already anticipates a miss. When the company does miss but the results aren't as bad as fe

[ad_1] Another disappointing quarter for Tesla served as just another speed bump for shareholders. Shares plummeted more than 12% Thursday as the Elon Musk's electric carmaker warned about slowing growth. I want to deploy an options strategy to use this emotional overreaction as an opportunity to add to my Tesla position. The slowdown, of course, was not a news flash as we have seen Lithium futures tumble 80% in the last year. However, when coupled with the second consecutive quarter that Tesla missed earning expectations, nearly $100 billion in market cap rapidly evaporated. TSLA 5Y mountain Tesla, 5 years Tesla did not help themselves in the short-term, on the conference call by removing volume guidance for 2024 since it will be notably lower. Another concerning issue is Elon is asking for a 25% voting control. He currently owns 13% but, Musk holds nearly 300 million unexercised stock options representing another 9% of Tesla's 3.2 billion shares outstanding. Thus, invest

[ad_1] CNBC's Jim Cramer called out General Electric as a winner in the industrial sector for the strides it's making in nuclear power. GE's Verona Nuclear Fuel business said Wednesday it received approval from the U.S. Nuclear Regulatory Commission to manufacture, ship, and analyze the performance of higher enrichment fuel. These "regulatory milestones" will help the company "innovate to help our customers run their plants even more efficiently and be ready to support the next generation of reactor technology," according to the press release . GE shares were trading about 2% higher on the news. GE YTD mountain GE stock performance year to date. "[General Electric] just keeps going higher," Cramer said Wednesday. While that's mainly due to demand for its aircraft engines, Cramer added that investors "love any way to be able to make nuclear fuel work." In November 2021, GE announced plans to split and form three publicly trade

[ad_1] AT&T Inc : "It's not as bad as it used to be." Plug Power Inc : "[CEO] Andy Marsh has promised us profitably for a very long time. ... My bountiful patience is beginning to get tried." Devon Energy Corp : "Keep buying." Disclaimer: Cramer's Charitable Trust owns shares of Devon Energy. Jim Cramer's Guide to Investing Click here to download   Jim Cramer's Guide to Investing  at no cost to help you build long-term wealth and invest smarter. [ad_2] Source link https://worldnews2023.com/business/cramers-lightning-round-i-like-juniper-networks/?feed_id=293300&_unique_id=65fe472c5df52

[ad_1] Danaher (DHR) is a day away from shedding its environmental-and-applied solutions segment, and the Club holding's ability to deliver returns for shareholders appears stronger than ever. Those potential returns can come from two places: Danaher stock and shares of Veralto (VLTO), the soon-to-be-standalone company that's in the business of water quality. We see underappreciated value in Danaher, and a favorable setup for Veralto after it's spun off into a separate, publicly traded entity on Saturday. When we receive Veralto shares on Monday, as all Danaher shareholders will, we intend to keep them, based on their current expected value. Danaher has looked attractive in recent weeks – Jim Cramer called its stock a buy during the Club's September Monthly Meeting – and that appeal increased this week following a key step in the spin-off process. A "when-issued" market was established Wednesday for both Danaher and Veralto stock, providing a first look a

[ad_1] An old favorite is going back in the Bullpen, our watch list of stocks we're considering buying for the Club's portfolio. In addition to improving business trends and a cheap valuation, the thinking is that this particular stock could benefit further from the broadening market rally, which has seen the Dow Jones Industrial Average really come to life recently, logging its first 10-session winning streak since August 2017. (Coming soon, we'll have another bullpen name that's tech-focused and benefits from AI chip development.) The stock we're adding first is DuPont (DD). We've profitably traded this specialty chemical maker for the Investing Club through the years — most recently selling it in the low $80s back in January 2022 after a valuation boost on the prospects of two pending deals. Only one was eventually completed. When we last owned DuPont, the company was waiting to close on its acquisition of Rogers Corporation , another specialty materials

[ad_1] A closely watched talc trial in California goes against Johnson & Johnson (JNJ), adding uncertainty around whether tens of thousands of other plaintiffs suing the company will sign on to J & J's proposed $8.9 billion settlement offer or seek to get their own days in court. Jim Cramer believes the biopharmaceutical company was "too hopeful" about winning. "The plaintiff system is stacked against them," Jim said. Still, he added, "I believe J & J is a great American company, I believe they'll see through this. ... They need to be a bit more realistic about what they say." Jim's conversations with J & J's legal team led him to believe there could be a path to victory in what we think is a pivotal case . But on Tuesday, J & J was ordered to pay $18.8 million after jurors found in favor of 24-year-old Emory Hernandez Valadez who claimed in his lawsuit that he developed mesothelioma, a deadly cancer linked to asbes

[ad_1] Send your questions directly to Jim Cramer and his team of analysts at investingclubmailbag@cnbc.com . Reminder, we can't offer personal investing advice. We will only consider more general questions about the investment process or stocks in the portfolio or related industries. Question 1: What are your thoughts on the stability of FORD's dividend? Thank you, Denise The quickest way to determine the sustainability of a company's dividend is to consider it in relation to earnings and/or cash flow. The dividend payout divided by the earnings number is referred to as the "payout ratio" — below 100% is generally considered sustainable (so long as it's positive). A negative number would imply negative earnings, which is obviously bad. A payout ratio above 100% would also be something to be concerned about because it means the company is paying out more than it makes and therefore eating into the cash on its balance sheet, an obviously unsustainable dyna

[ad_1] Two weeks into the second half of the year, we put together a quick look at the top four performers and the bottom four in Jim Cramer's Charitable Trust, the stock portfolio we use for the Investing Club. The first full trading week of July saw Wall Street under some pressure Friday after a multisession winning streak. Gains month-to-date of roughly 2.4% for the Nasdaq add to the tech-heavy index's best first half (up nearly 32%) in four decades. There are some new names on both the July leaders and July laggards list since we did this exercise looking at our January to June portfolio performance. July leaders HAL mountain 2023-06-30 Halliburton stock performance since June 30 close Oilfield services giant Halliburton (HAL) flips from a first-half loser (down 16%) to top our second-half winner. Month-to-date, HAL gained nearly 12%, a recent rally that we took advantage of Friday morning by booking in some profits. During our Monthly Meeting on Wednesday, we told mem

[ad_1] Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Monday's key moments. Earnings and inflation Watch J & J Strong outlook for Meta 1. Earnings and inflation U.S. stocks edged higher Monday, with the Dow jumping over 150 points, rallying after a tough week for the major Wall Street gauges. We're looking ahead to second-quarter earnings Friday, kicking off with financials like Club holding Wells Fargo (WFC). Consumer price index (CPI) data will be released Wednesday, which will give the market a better read on the inflation situation. Overall, there's a lot of uncertainty for the U.S. economy as inflation stays high and the Federal Reserve mulls over further monetary tightening in order to cool a resilient labor market. 2. Watch J & J We're watching for closing arguments in a talc lawsuit against Johnson & Johnson (JNJ) brought by a 24-year-old in California